HEPALINK - Announcement of Resolutions of the 20th Meeting of the 6th Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
HEPALINK - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
does not make any representation as to its accuracy or completeness and expressly disclaims all or any liability arising out of or in connection with this announcement. assumes no responsibility for any loss arising from any part of the content or arising from reliance on such content.
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (Shenzhen Hepalink Pharmaceutical Group Co., Ltd.) (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 9989)
Overseas regulatory announcement
This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company") pursuant to the Hong Kong Stock Exchange
made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities of Limited Company.
The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.
By order of the board of directors Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li Chairman
Shenzhen, China, March 30, 2026
As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; The independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.
Securities code: 002399 Securities abbreviation: Hepalink Announcement number: 2026-002
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 20th Meeting of the Sixth Board of Directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate, complete and not false.
Records, misleading statements or material omissions.
- Convening of board of directors meetings
The sixth session of the Board of Directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company")
The notice and resolutions of the 20th meeting (hereinafter referred to as the "meeting") were sent by email on March 16, 2026.
The form will be issued and the meeting will be held at 14:00 pm on March 30, 2026 at 21 Langshan Road, Songpingshan, Nanshan District, Shenzhen The conference room was held in a combination of on-site and communication methods. 7 directors should participate in the voting at this meeting, but actually participated
There were 7 voting directors, among whom Mr. Zhang Ping participated in the voting by communication. Senior managers of the company attended
The meeting was chaired by Mr. Li Li, chairman of the company. Notice, convening of this meeting and directors participating in voting
The number of participants complies with relevant laws, regulations and the relevant provisions of the Articles of Association.
- Review status of board of directors meeting
The following proposals were carefully considered and approved by the directors present at the meeting:
- "2025 Board of Directors Work Report"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the "2025 Annual Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.
"Section 3: Management Discussion and Analysis" and "Section 4: Corporate Governance, Environment and Society" in the "Performance Report".
The company's independent directors Huang Peng, Yi Ming, Pu Hong and Lu Chuan (retired) submitted the "2025 Plan" to the board of directors.
"Duty Report of Independent Directors" and will take office at the company's 2025 annual shareholders' meeting. The current independent director
The company’s board of directors submitted the “Independent Directors’ Self-Inspection Report on Independence”, which the company’s board of directors conducted The Bank evaluated and issued the "Special Opinions of the Board of Directors on the Independence Assessment of Independent Directors in 2025".
For details, please refer to the "2025 Annual Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.
Independent Directors' Work Report" and "Special Opinions of the Board of Directors on the Independence Assessment of Independent Directors in 2025".
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "2025 General Manager Work Report"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
The general manager reports to the board of directors on the company's operating conditions in 2025 and the work plan for 2026.
Reviewed and approved.
- "2025 Annual Report" and its summary, H-share "2025 Performance Announcement", H-share "2025 Annual Report"
Annual Report" "Corporate Governance Report 2025"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the "2025 Annual Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day. Report"; disclosed on the same day in "Securities Times", "China Securities News", "Shanghai Securities News" and "Securities Daily"
and the "2025 Annual Report Summary" of the Juchao Information Network www.cninfo.com.cn; and disclosed in Hong Kong on the same day
H shares on the website of The United Exchange Limited at www.hkexnews.hk and the Company’s website at www.hepalink.com
"2025 Results Announcement".
The company prepares the H-share "2025 Annual Report" and H-shares in accordance with the Hong Kong Stock Exchange Listing Rules.
H-shares' 2025 Corporate Governance Report, and agreed to authorize the joint company secretary to approve the H-shares' 2025 Corporate Governance Report upon completion of the review.
Annual Report" and "Corporate Governance Report 2025" shall be disclosed to the public at the time required by the Hong Kong Stock Exchange.
It can only be published on the website of the Hong Kong Stock Exchange and sent to H-share holders.
This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company.
- "Profit Distribution Plan for 2025"
The company's profit distribution plan for 2025 is: based on the total share capital of 1,467,296,204 shares at the end of 2025,
A cash dividend of RMB 1.45 (tax included) was distributed for every 10 shares, and a total cash dividend of RMB 212,757,949.58 was distributed. The remaining Profits are retained as undistributed profits. No bonus shares will be issued, and no capital reserve will be converted into capital.
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "Profit Distribution Plan for 2025"
Announcement".
This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company. This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Confirmation of Directors' 2025 Remuneration and 2026 Remuneration Plan"
Voting results: 0 votes in favor, 0 abstentions, and 0 votes against. (All directors abstained from voting)
For details of the company’s directors’ remuneration in 2025, please see the company’s disclosure on the cncn.info.com on the same day. "Section 4 Corporate Governance, Environment and Society" in the "2025 Annual Report" of www.cninfo.com.cn
Related content. The remuneration plan for directors in 2026 is:
The remuneration of non-independent directors (including employee representative directors) who hold management functions in the company will be based on the Company's "Articles of Association", "Remuneration and Appraisal System for Directors and Senior Management" and other relevant provisions as well as annual operating performance evaluation
Determined after review, including basic salary, performance pay and statutory social security benefits.
Independent directors receive remuneration based on the work allowance standards for independent directors approved by the shareholders' meeting. Independent directors perform Expenses incurred for the duties shall be reimbursed by the company according to the actual situation.
This proposal has been reviewed at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the company, and all members
Avoid voting and this proposal will be directly submitted to the company's board of directors for review. All directors of the company have abstained from expressing their opinions on this proposal. Resolution, this proposal will be directly submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Confirming the 2025 Remuneration and 2026 Remuneration Plan for Senior Management"
Voting results: 5 votes in favor, 0 abstentions, and 0 votes against. (Associated directors Ms. Li Tan and Mr. Shan Yu
avoid voting)
For details of the company’s senior management salary situation in 2025, please refer to the company’s disclosure on cninfo.com on the same day.
"Section 4 Corporate Governance, Environment and Society" in the "2025 Annual Report" of www.cninfo.com.cn
Related content. The salary plan for senior management personnel in 2026 is:
The senior managers of the company shall, according to the specific management positions they hold in the company, according to the "Articles of Association" and "Directors".
"Remuneration and Appraisal System for General Managers and Senior Management Personnel" and other relevant regulations, combined with actual operating performance, personal performance
Receive remuneration upon completion of responsibilities and objectives.
This proposal has been unanimously approved for review at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the Company.
Passed. The remuneration situation of the company's senior managers in 2025 will be reported to the company's shareholders' meeting.
- "2025 Internal Control Evaluation Report"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the "2025 Annual Report" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.
Internal Control Evaluation Report”.
This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company.
- "Proposal on using own funds to purchase financial products and conduct cash management"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "About Using Own Funds to Purchase Financial Management" Announcement on Products and Cash Management.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Carrying out Foreign Exchange Derivatives Transactions for the Purpose of Hedging"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "About Carrying out Hedging Purposes"
"Announcement on Foreign Exchange Derivatives Trading", please refer to the relevant feasibility analysis disclosed on the cninfo.com on the same day. "On the Feasibility of Carrying out Foreign Exchange Derivatives Transactions for Hedging Purposes" from www.cninfo.com.cn
Analysis Report".
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Applying for Credit Lines from Banks and Providing Guarantees in 2026"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "About applying for credit from banks in 2026" Quota and Announcement on Provision of Guarantee.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Changing the Use of Funds Raised by H Shares"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "About changing the use of funds raised from H shares"
Announcement of the journey.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "The Audit Committee of the Board of Directors evaluates and supervises the accounting firm's performance of duties in 2025"
Responsibility Report》
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the "Board Review" disclosed by the company on the cninfo website www.cninfo.com.cn on the same day.
"Report on the Accounting Firm's Assessment of Duty Performance and Supervision Responsibilities of the Accounting Firm in 2025 by the Accounting Committee".
This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company.
- "Proposal on Re-appointment of Accounting Firm"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "Announcement on Re-appointment of Accounting Firms" Report".
This proposal has been unanimously approved at the 13th meeting of the Audit Committee of the sixth session of the Board of Directors of the company.
This proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on the general election of the Board of Directors and the nomination of non-independent director candidates for the seventh Board of Directors"
In view of the fact that the term of the company's sixth board of directors is about to expire, the company will replace the board of directors in accordance with relevant legal procedures.
election. After the nomination committee of the sixth session of the board of directors reviewed the candidates’ qualifications, the company’s board of directors agreed to propose
Mr. Li Li, Ms. Li Tan and Mr. Shan Yu are candidates for the non-independent directors of the seventh session of the Board of Directors of the company, and their terms of office are
It shall be three years from the date of approval by the company's shareholders' meeting.
The directors present at the meeting voted on the above candidates item by item, and the voting results are as follows:
14.01. Nominate Mr. Li Li as a non-independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
14.02. Nominate Ms. Li Tan as a non-independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
14.03. Nominate Mr. Shan Yu as a non-independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Announcement on the General Election of the Board of Directors" from "Securities Daily" and www.cninfo.com.cn.
This proposal has been unanimously approved at the fifth meeting of the Nomination Committee of the sixth session of the Board of Directors of the company. Ben
The proposal still needs to be submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on the General Election of the Board of Directors and Nomination of Independent Director Candidates for the Seventh Board of Directors"
In view of the fact that the term of the company's sixth board of directors is about to expire, the company will replace the board of directors in accordance with relevant legal procedures.
election. After the nomination committee of the sixth session of the board of directors reviewed the candidates’ qualifications, the company’s board of directors agreed to propose Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong are candidates for independent directors of the seventh session of the Board of Directors of the company, with a term of
Three years from the date of approval by the company's shareholders' meeting.
The directors present at the meeting voted on the above candidates item by item, and the voting results are as follows:
15.01. Nominate Mr. Huang Peng as an independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
15.02. Nominate Mr. Yi Ming as an independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
15.03. Nominate Mr. Pu Hong as an independent director candidate for the company’s seventh board of directors
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Announcement on the General Election of the Board of Directors" from "Securities Daily" and www.cninfo.com.cn.
This proposal has been unanimously approved at the fifth meeting of the Nomination Committee of the sixth session of the Board of Directors of the company. on The qualifications and independence of the independent director candidates mentioned above are subject to review by Shenzhen Stock Exchange and other relevant departments.
Only after objections have been raised can it be submitted to the company's shareholders' meeting for review.
- "Proposal on the remuneration of directors and allowances for independent directors of the seventh session of the Board of Directors"
In accordance with the "Code of Corporate Governance for Listed Companies", "Measures for the Administration of Independent Directors of Listed Companies" and "Articles of Association"
Relevant regulations and based on the company's actual situation, the company's seventh board of directors' remuneration and independent director allowances are formulated.
The plan is as follows:
The remuneration of non-independent directors (including employee representative directors) who hold management functions in the company will be based on the Company's
"Articles of Association", "Remuneration and Appraisal System for Directors and Senior Management" and other relevant provisions as well as annual operating performance evaluation
Determined after review, including basic salary, performance pay and statutory social security benefits.
Independent directors have a fixed allowance of RMB 100,000 per person per year (tax included), on a monthly basis.
issued. The expenses incurred by independent directors in performing their duties shall be reimbursed by the company according to the facts.
Voting results: 0 votes in favor, 0 abstentions, and 0 votes against. (All directors abstained from voting)
This proposal has been reviewed at the fifth meeting of the Remuneration and Appraisal Committee of the sixth session of the Board of Directors of the company, and all members Avoid voting and this proposal will be directly submitted to the company's board of directors for review. All directors of the company have abstained from expressing their opinions on this proposal.
Resolution, this proposal will be directly submitted to the company's 2025 annual shareholders' meeting for review.
- "Proposal on Proposing to Convene the 2025 Annual Shareholders Meeting"
Voting results: 7 votes in favor, 0 abstentions, and 0 votes against.
For details, please refer to the company’s disclosures in Securities Times, China Securities Journal and Shanghai Securities News on the same day.
"Securities Daily" and Juchao Information Network www.cninfo.com.cn's "Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Co., Ltd.’s Notice on Convening the 2025 Annual Shareholders Meeting”.
Documents available for inspection
Resolution of the 20th meeting of the 6th Board of Directors
Resolution of the 13th meeting of the Audit Committee of the 6th Board of Directors
Resolution of the fifth meeting of the Remuneration and Appraisal Committee of the Sixth Board of Directors
Resolution of the fifth meeting of the Nomination Committee of the Sixth Board of Directors
Announcement is hereby made.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
board of directors
March 31, 2026